Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy

Radiation Oncology

Eric Lartigau¹  Claire Dewas-Vautravers¹  Thomas Lacornerie¹  Hajer Jarraya³  Andrew Kramar²  Ingrid Fumagalli¹  Xavier Mirabel¹  Jean-Emmanuel Bibault¹  Sylvain Dewas³ 

[1] Academic Radiation Oncology Department & University Lille II, CLCC Oscar Lambret, 3 rue Frederic Combemale, BP 307, Lille cedex, 59 020, France;Methodology and Biostatistics Unit, CLCC Oscar Lambret, 3 rue Frederic Combemale, BP 307, Lille cedex, 59 020, France;Department of Radiology, CLCC Oscar Lambret, 3 rue Frederic Combemale, BP 307, Lille cedex, 59 020, France

关键词: Prognostic fractors;    Local control;    SBRT;    Liver metastases;    Hepatocellular carcinoma;   

Others  :  1155246
DOI  :  10.1186/1748-717X-7-166

 received in 2012-03-26, accepted in 2012-09-26,  发布年份 2012

【 摘 要 】

Purpose

Robotic Stereotactic Body Radiation Therapy with real-time tumor tracking has shown encouraging results for hepatic tumors with good efficacy and low toxicity. We studied the factors associated with local control of primary or secondary hepatic lesions post-SBRT.

Methods and materials

Since 2007, 153 stereotactic liver treatments were administered to 120 patients using the CyberKnife® System. Ninety-nine liver metastases (72 patients), 48 hepatocellular carcinomas (42 patients), and six cholangiocarcinomas were treated. On average, three to four sessions were delivered over 12 days. Twenty-seven to 45 Gy was prescribed to the 80% isodose line. Margins consisted of 5 to 10 mm for clinical target volume (CTV) and 3 mm for planning target volume (PTV).

Results

Median size was 33 mm (range, 5–112 mm). Median gross tumor volume (GTV) was 32.38 cm³ (range, 0.2–499.5 cm³). Median total dose was 45 Gy in three fractions. Median minimum dose was 27 Gy in three fractions. With a median follow-up of 15.0 months, local control rates at one and two years were 84% and 74.6%, respectively. The factors associated with better local control were lesion size < 50 mm (p = 0.019), GTV volume (p < 0.05), PTV volume (p < 0.01) and two treatment factors: a total dose of 45 Gy and a dose–per-fraction of 15 Gy (p = 0.019).

Conclusions

Dose, tumor diameter and volume are prognostic factors for local control when a stereotactic radiation therapy for hepatic lesions is considered. These results should be considered in order to obtain a maximum therapeutic efficacy.

【 授权许可】

   
2012 Dewas et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ambrosino G, Polistina F, Costantin G, et al.: Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res 2009, 29:3381-3384.
• [2]Cárdenes HR: Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results. Clin Transl Oncol 2009, 11:276-283.
• [3]Goodman KA, Wiegner EA, Maturen KE, et al.: Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 2010, 78:486-493.
• [4]van der Pool AEM, Méndez Romero A, Wunderink W, et al.: Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 2010, 97:377-382.
• [5]Bruix J, Sherman M, Llovet JM, et al.: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
• [6]Wulf J, Hädinger U, Oppitz U, et al.: Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 2001, 177:645-655.
• [7]Choi BO, Choi IB, Jang HS, et al.: Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer. 2008, 8:351. BioMed Central Full Text
• [8]Kang J-K, Kim M-S, Cho CK, et al.: Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012. [published online ahead of print May 8 2012]. Accessed October 1, 2012
• [9]O’Connor JK, Trotter J, Davis GL, et al.: Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012, 18:949-954.
• [10]Huang W-Y, Jen Y-M, Lee M-S, et al.: Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2012, 84:355-361.
• [11]Kopek N, Holt MI, Hansen AT, Høyer M: Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 2010, 94:47-52.
• [12]Barney BM, Olivier KR, Miller RC, Haddock MG: Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol 2012, 7:67. BioMed Central Full Text
• [13]Herfarth KK, Debus J, Lohr F, et al.: Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001, 19:164-170.
• [14]Herfarth KK, Debus J: Stereotactic radiation therapy for liver metastases. Chirurg 2005, 76:564-569.
• [15]Rusthoven KE, Kavanagh BD, Cardenes H, et al.: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009, 27:1572-1578.
• [16]McCammon R, Schefter TE, Gaspar LE, et al.: Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2009, 73:112-118.
• [17]Dawson LA, McGinn CJ, Normolle D, et al.: Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000, 18:2210-2218.
• [18]Park HC, Seong J, Han KH, et al.: Dose–response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002, 54:150-155.
• [19]Wada H, Takai Y, Nemoto K, Yamada S: Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors. Int J Radiat Oncol Biol Phys 2004, 58:1114-1120.
• [20]Blomgren H, Lax I, Näslund I, Svanström R: Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator: clinical experience of the first thirty-one patients. Acta Oncol 1995, 34:861-870.
• [21]Schefter TE, Kavanagh BD, Timmerman RD, et al.: A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005, 62:1371-1378.
• [22]Méndez Romero A, Wunderink W, Hussain SM, et al.: Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 2006, 45:831-837.
• [23]Hoyer M, Roed H, Traberg Hansen A, et al.: Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006, 45:823-830.
• [24]Kavanagh BD, Schefter TE, Cardenes HR, et al.: Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 2006, 45:848-855.
• [25]Katz AW, Carey-Sampson M, Muhs AG, et al.: Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 2007, 67:793-798.
• [26]Tse RV, Hawkins M, Lockwood G, et al.: Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008, 26:657-664.
• [27]Lee MT, Kim JJ, Dinniwell R, et al.: Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009, 27:1585-1591.
• [28]Cárdenes HR, Price TR, Perkins SM, et al.: Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010, 12:218-225.